glp 1 and heart failure New Mechanisms to Prevent with Preserved Ejection Fraction Using Glucagon-like Peptide-1 Receptor Agonism (GLP-1 RA) in Metabolic Syndrome in Type 2 Diabetes: A Review Increased Risk of Heart Failure

The analysis revealed that participants receiving cagrilintide plus semaglutide achieved a mean 20.4% reduction in body weight at 68 weeks, compared with a 3.0% reduction with placebo (estimated difference, -17.3 percentage points

These events were predominantly mild to moderate and transient, and only 5.9% of participants discontinued treatment, indicating an overall acceptable safety and tolerability profile

Personalized adjustments are often needed based on individual health status and goals

Furthermore, the peptide lowers the level of chromosomal instability in patients with hypertrophic cardiomyopathy (HCM), a hereditary disease that affects the heart muscle, and their relatives

Jian R, Xueqin W, Pan C, et al